Literature DB >> 8102408

Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.

S J Vukelja, W J Baker, H A Burris, J H Keeling, D Von Hoff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102408     DOI: 10.1093/jnci/85.17.1432

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  7 in total

1.  [Palmoplantar erythrodysesthesia after intravenous therapy with docetaxel].

Authors:  S Meller; J Reifenberger; H Stege; T Ruzicka; B Homey
Journal:  Hautarzt       Date:  2005-10       Impact factor: 0.751

2.  [Hand-foot syndrome with capecitabine therapy].

Authors:  A Marini; U R Hengge
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

3.  Cutaneous Toxicity in a Laboratory Beagle (Canis lupus familiaris) after Chronic Administration of Doxorubicin Hydrochloride.

Authors:  Kathryn A Guerriero; Steven R Wilson; Nabil E Boutagy; Chi Liu; Albert J Sinusas; Caroline J Zeiss
Journal:  Comp Med       Date:  2018-02-01       Impact factor: 0.982

Review 4.  Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Authors:  Carla C P Verstappen; Jan J Heimans; Klaas Hoekman; Tjeerd J Postma
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.

Authors:  Hyun-Sook Son; Woo Yong Lee; Won-Suk Lee; Seong Hyeon Yun; Ho-Kyung Chun
Journal:  Yonsei Med J       Date:  2009-12-18       Impact factor: 2.759

Review 6.  Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.

Authors:  Min Chen; Lingli Zhang; Qian Wang; Jiantong Shen
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

7.  Hand-foot syndrome with docetaxel: a five-case series.

Authors:  Mirna H Farhat; Nagi S El-Saghir; Ali I Shamseddine
Journal:  Ann Saudi Med       Date:  2008 Sep-Oct       Impact factor: 1.526

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.